title: Endothelin-2 signaling in the neural retina promotes the endothelial tip cell state and inhibits angiogenesis.
abstract: Endothelin signaling is required for neural crest migration and homeostatic regulation of blood pressure. Here, we report that constitutive overexpression of Endothelin-2 (Edn2) in the mouse retina perturbs vascular development by inhibiting endothelial cell migration across the retinal surface and subsequent endothelial cell invasion into the retina. Developing endothelial cells exist in one of two states: tip cells at the growing front and stalk cells in the vascular plexus behind the front. This division of endothelial cell states is one of the central organizing principles of angiogenesis. In the developing retina, Edn2 overexpression leads to overproduction of endothelial tip cells by both morphologic and molecular criteria. Spatially localized overexpression of Edn2 produces a correspondingly localized endothelial response. Edn2 overexpression in the early embryo inhibits vascular development at midgestation, but Edn2 overexpression in developing skin and brain has no discernible effect on vascular structure. Inhibition of retinal angiogenesis by Edn2 requires expression of Endothelin receptor A but not Endothelin receptor B in the neural retina. Taken together, these observations imply that the neural retina responds to Edn2 by synthesizing one or more factors that promote the endothelial tip cell state and inhibit angiogenesis. The response to Edn2 is sufficiently potent that it overrides the activities of other homeostatic regulators of angiogenesis, such as Vegf.
authors.affiliation: Departments of Molecular Biology and Genetics, Neuroscience, and Ophthalmology and Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
authors.forename: Amir
authors.initials: A
authors.lastname: Rattner
authors.forename: Huimin
authors.initials: H
authors.lastname: Yu
authors.forename: John
authors.initials: J
authors.lastname: Williams
authors.forename: Philip M
authors.initials: PM
authors.lastname: Smallwood
authors.forename: Jeremy
authors.initials: J
authors.lastname: Nathans
mesh_terms: D020533:Angiogenesis Inhibitors / Q000378:metabolism*; D000818:Animals; D001483:Base Sequence; D042783:Endothelial Cells / Q000166:cytology / Q000502:physiology*; D019333:Endothelin-2 / Q000378:metabolism*; D006651:Histocytochemistry; D017403:In Situ Hybridization; D051379:Mice; D046228:Microarray Analysis; D008969:Molecular Sequence Data; D044022:Receptor, Endothelin A / Q000378:metabolism*; D012171:Retinal Vessels / Q000196:embryology* / Q000378:metabolism; D017423:Sequence Analysis, RNA; D015398:Signal Transduction / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; D019333:Endothelin-2; D044022:Receptor, Endothelin A
references.citation: Cell. 2011 Sep 16;146(6):873-87
references.pmid: 21925313
references.citation: Blood. 2010 Nov 11;116(19):4025-33
references.pmid: 20705756
references.citation: Nat Protoc. 2008;3(11):1703-8
references.pmid: 18846097
references.citation: J Neurosci. 2005 May 4;25(18):4540-9
references.pmid: 15872101
references.citation: Trends Mol Med. 2010 Sep;16(9):417-25
references.pmid: 20688566
references.citation: Dev Biol. 2000 Jun 15;222(2):296-306
references.pmid: 10837119
references.citation: Dev Cell. 2002 Sep;3(3):411-23
references.pmid: 12361603
references.citation: Mol Vis. 2005 Apr 28;11:298-308
references.pmid: 15889014
references.citation: Nature. 2005 Dec 15;438(7070):960-6
references.pmid: 16355161
references.citation: Nature. 2007 Feb 15;445(7129):776-80
references.pmid: 17259973
references.citation: Annu Rev Pharmacol Toxicol. 2001;41:851-76
references.pmid: 11264479
references.citation: Thromb Haemost. 2007 Jan;97(1):99-108
references.pmid: 17200776
references.citation: Dev Dyn. 2005 Jun;233(2):407-17
references.pmid: 15768389
references.citation: Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2813-26
references.pmid: 20484600
references.citation: Nat Cell Biol. 2010 Oct;12(10):943-53
references.pmid: 20871601
references.citation: Cytokine Growth Factor Rev. 2004 Aug;15(4):205-13
references.pmid: 15207812
references.citation: Genesis. 2000 Feb;26(2):130-2
references.pmid: 10686607
references.citation: J Cell Biol. 2003 Jun 23;161(6):1163-77
references.pmid: 12810700
references.citation: Cell. 2001 Apr 6;105(1):43-55
references.pmid: 11301001
references.citation: Curr Diab Rep. 2012 Aug;12(4):355-63
references.pmid: 22638940
references.citation: Development. 2004 Jul;131(14):3239-47
references.pmid: 15201217
references.citation: Exp Cell Res. 2006 Mar 10;312(5):676-83
references.pmid: 16337189
references.citation: Cell. 2009 Oct 16;139(2):285-98
references.pmid: 19837032
references.citation: Cell. 2012 Dec 7;151(6):1332-44
references.pmid: 23217714
references.citation: Nat Cell Biol. 2011 Sep 11;13(10):1202-13
references.pmid: 21909098
references.citation: Genes Dev. 2011 Jul 1;25(13):1399-411
references.pmid: 21724832
references.citation: Genesis. 2007 Sep;45(9):593-605
references.pmid: 17868096
references.citation: Blood. 2010 Jun 17;115(24):5102-10
references.pmid: 20154215
references.citation: Development. 2011 Nov;138(21):4763-76
references.pmid: 21965612
references.citation: Oncogene. 2003 Aug 21;22(35):5415-26
references.pmid: 12934101
references.citation: Angiogenesis. 2007;10(2):77-88
references.pmid: 17322966
references.citation: Br J Cancer. 1987 Oct;56(4):395-400
references.pmid: 3689657
references.citation: Nature. 2012 Mar 18;484(7392):110-4
references.pmid: 22426001
references.citation: Nature. 1988 Mar 31;332(6163):411-5
references.pmid: 2451132
references.citation: Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3329-40
references.pmid: 17591906
references.citation: Cell. 2009 Jun 12;137(6):1124-35
references.pmid: 19524514
references.citation: Curr Opin Cell Biol. 2010 Oct;22(5):617-25
references.pmid: 20817428
references.citation: Exp Eye Res. 2012 Jun;99:17-26
references.pmid: 22546314
references.citation: Dev Biol. 2009 Apr 1;328(1):94-108
references.pmid: 19185569